Climate Compass on MSNOpinion
LED blue light risk: The health warning lighting brands don't have to share
When you flip a switch or power up your smartphone, the last thing on your mind is whether that light could be messing with ...
Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...
Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...
An international research team led by Prof. Dr. Sedat Nizamoğlu from the Department of Electrical and Electronics Engineering ...
Plotting a challenge to Regeneron’s blockbuster Eylea, Ocular Therapeutix has hired “a key architect” of its rival’s launch ...
Outlook Therapeutics shares slid after the company's macular degeneration drug was once again rejected by the Food and Drug Administration. The stock dropped 71% to 45 cents a share in after-hours ...
By 2050, an estimated 50% of the world's population will be nearsighted, and nearly a billion people will suffer from severe ...
The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...
Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...
The long-living sharks aren't as blind as once thought and have DNA repair mechanisms that may help prevent their vision from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results